{Reference Type}: Journal Article
{Title}: Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach.
{Author}: Mustea A;Ralser DJ;Egger EK;Ziehm U;Vivas S;Brock S;Jackson D;Condic M;Rauschendorf MA;Würfel P;Dombrowski F;Otten LA;Sun P;Laib A;Cordova MC;Hartmann R;Stein MA;Koensgen D;Stope MB;
{Journal}: J Cancer Res Clin Oncol
{Volume}: 150
{Issue}: 7
{Year}: 2024 Jul 25
{Factor}: 4.322
{DOI}: 10.1007/s00432-024-05901-4
{Abstract}: <B>OBJECTIVE: </B>Endometrial cancer (EC) is heterogeneous with respect to epidemiology, clinical course, histopathology and tumor biology. Recently, The Cancer Genome Atlas (TCGA) network has identified four molecular subtypes with distinct clinical courses by an integrated multi-omics approach. These subtypes are of critical importance in the clinical management of EC. However, determination of TCGA molecular subtypes requires a complex methodological approach that is resource intensive and difficult to implement in diagnostic routine procedures. In this context, Talhouk et al. reported the precise determination of modified subtypes based on molecular surrogates obtained by a two-method approach comprising immunohistochemistry and DNA-sequence analysis (Proactive Molecular Risk Classifier for Endometrial Cancer; ProMisE). In this study, we aimed to identify EC molecular subtypes in analogy to TCGA and ProMisE applying an innovative whole exome-sequencing (WES) based single-method approach.<BR><B>METHODS: </B>WES was performed in a cohort comprising N = 114 EC patients. WES data were analyzed using the oncology treatment decision support software MH Guide (Molecular Health, Heidelberg, Germany) and EC molecular subtypes in analogy to TCGA and ProMisE were determined. Results from both classifications were compared regarding their prognostic values using overall survival and progression-free survival analyses.<BR><B>RESULTS: </B>Applying a single-method WES-approach, EC molecular subtypes analogue to TCGA and ProMisE were identified in the study cohort. The surrogate marker-analogue classification precisely identified high-risk and low-risk EC, whereas the TCGA-analogue classification failed to obtain significant prognostic values in this regard.<BR><B>CONCLUSIONS: </B>Our data demonstrate that determination of EC molecular subtypes analogue to TCGA and ProMisE is feasible by using a single-method WES approach. Within our EC cohort, prognostic implications were only reliably provided by applying the surrogate marker-analogue approach. Designation of molecular subtypes in EC will be increasingly important in routine clinical practice. Thus, the single-method WES approach provides an important simple tool to tailor therapeutic decisions in EC.